Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of a personalized, strike early and strong approach on non-HDL-cholesterol levels and outcome in patients with acute myocardial infarction.

International journal of cardiology·2025

Same author

Right ventricular strain predicts outcome in patients receiving sacubitril/valsartan: A sub-analysis of DISCOVER-ARNI.

ESC heart failure·2025

Same author

Distal Radial Artery Approach for Invasive Blood Pressure Monitoring in Intensive Cardiac Care Unit.

The American journal of cardiology·2025

Same author

Arrhythmic Risk Stratification and Sudden Cardiac Death Prevention in Duchenne Muscular Dystrophy: A Critical Appraisal.

Reviews in cardiovascular medicine·2025

Same author

A case report of long COVID-19 and chronic active myocarditis.

European heart journal. Case reports·2025

Same author

Characterization of Circulating Vesicles of Complicated and Uncomplicated Systemic Sclerosis Patients and Their Role in Vascular Dysfunction.

International journal of molecular sciences·2025

Search research articles

Related Experiment Videos

Contemporary issues on clopidogrel therapy.

Giuseppe Patti¹, Germano Di Sciascio

¹Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy. g.patti@unicampus.it

Internal and Emergency Medicine

|January 9, 2009

Summary

This summary is machine-generated.

This review analyzes clopidogrel therapy for acute coronary syndromes. It addresses optimal timing, dosing, and pre-treatment strategies for percutaneous coronary intervention (PCI) and their impact on patient outcomes.

Related Experiment Videos

Area of Science:

Cardiology
Pharmacology
Clinical Medicine

Background:

Clopidogrel is a crucial antiplatelet medication for acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI).
Optimal use of clopidogrel therapy remains a subject of ongoing clinical research and debate.
Understanding clopidogrel's role in various treatment scenarios is vital for improving patient care.

Purpose of the Study:

To analyze current data on key clinical questions regarding clopidogrel therapy in ACS and PCI.
To evaluate the necessity and timing of early clopidogrel treatment.
To determine optimal dosing and pre-treatment strategies for clopidogrel in PCI patients.

Main Methods:

Systematic review and analysis of available studies on clopidogrel therapy.
Focused evaluation of clinical questions related to ACS management and PCI procedures.
Assessment of clopidogrel response and its correlation with clinical outcomes.

Main Results:

Early clopidogrel treatment is generally beneficial for patients with ACS, whether managed medically or with PCI.
Optimal loading dose and pre-treatment timing for PCI require careful consideration based on individual patient factors.
The degree of clopidogrel response significantly influences clinical outcomes in patients undergoing PCI.

Conclusions:

Evidence supports early initiation of clopidogrel therapy in ACS patients.
Personalized clopidogrel strategies, including dose and timing, are essential for optimizing outcomes in PCI.
Monitoring clopidogrel response can help tailor therapy and improve clinical results in patients undergoing PCI.